Shares of Can-Fite Biopharma Ltd (NASDAQ:CANF) have received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.
Brokers have set a twelve-month consensus price target of $19.49 for the company and are predicting that the company will post ($0.80) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Can-Fite Biopharma an industry rank of 87 out of 256 based on the ratings given to its competitors.
Separately, HC Wainwright reaffirmed a “buy” rating on shares of Can-Fite Biopharma in a research note on Tuesday, March 26th.
Can-Fite Biopharma (NASDAQ:CANF) last announced its quarterly earnings data on Wednesday, May 29th. The company reported ($1.20) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.94) by $0.74. The firm had revenue of $0.30 million for the quarter.
Can-Fite Biopharma Company Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.
Featured Story: Trading Ex-Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Can-Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.